AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04453189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Participants will receive lansoprazole once daily in fasted condition on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5 in assigned treatment sequence.
Study NCT01895738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WrapAround Care
Description: Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
Study NCT00436943 — intervention group
Intervention type: DRUG
Intervention: nicotine replacement therapy and bupropion
Description: 3-6 months
Study NCT00436943 — intervention group
Intervention type: BEHAVIORAL
Intervention: smoking cessation counseling and referrals
Description: Organizational counseling and referrals
Study NCT02766244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICG/SPY
Description: indocyanine green fluorescence imaging
Study NCT02766244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic Ointment
Description: Antibiotic ointment
Study NCT00714259 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2/day x 3 days
Study NCT02710669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (R)-propafenone
Study NCT02710669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (S)-Propafenone
Study NCT02710669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00576485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery and intraocular lens implantation
Description: Cataract surgery and implantation of an intraocular lens
Study NCT01491100 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Patients treated with regular dose subcutaneously administered, according to the label and to clinical routine practice.
Study NCT03105024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement
Description: specific instructions regarding the retrieval of mastery experiences during exposure will be given (e.g., pointing out discrepancies between expected negative consequences and actual outcome during exposure; focus on achievements)
Study NCT00714259 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Total Body Irradiation
Description: TBI 200cGy x1 dose on transplant day
Study NCT00714259 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Infusion of Stem Cells
Description: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10\*6 CD34+ cells per kilogram of recipient weight.
Study NCT02835274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BSC Deep Brain Stimulation System with Directional Lead
Study NCT02835274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BSC Deep Brain Stimulation System with Directional Lead
Study NCT00872131 — intervention group
Intervention type: DRUG
Intervention: Sertraline
Description: Oral sertraline will begin at 50 mg per day, then increase to 75 mg per day on Day 8, then increase to 100 mg per day on Day 15. The dose may be increased to 150 mg per day on Week 8, based on clinical response and medication toleration.
Study NCT00211536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medtronic MiniMed Implantable Pump Human Recombinant Insulin
Description: 400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
Study NCT00211536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic MiniMed Implantable Pump System
Description: The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.
Study NCT00211536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aventis HOE21PH U400
Description: 400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
Study NCT03164291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
Study NCT00003855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary lymph node dissection
Study NCT00003855 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole breast irradiation
Study NCT00003855 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole breast irradiation
Study NCT01829529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin
Study NCT03715127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybine oral capsule
Description: single dose of psilocybin (0.215mg / kg body weight)
Study NCT03715127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: single dose of placebo (100% mannitol)
Study NCT02735876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Study NCT02735876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibrutinib
Study NCT02735876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT04067076 — intervention group
Intervention type: OTHER
Intervention: Self-administered evaluation questionnaire
Description: Smartphone app with MeMind questionnaires
Study NCT00206752 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: definitive external beam radiation in the ipsilateral neck.
Study NCT00206752 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: definitive external beam radiation in the ipsilateral neck
Description: definitive external beam radiation in the ipsilateral neck
Study NCT01639807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Latanoprost (0.005%) eye drops, once daily in the evening
Study NCT01639807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLT
Description: Selective Laser Trabeculoplasty
Study NCT00130754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobuline
Description: IV 7.5 mg/kg
Study NCT03484884 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cerenkov luminescence imaging.
Description: Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.
Study NCT04196231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDegLira
Description: IDegLira will be started at 16 dose steps (16 U insulin degludec plus 0.58 mg liraglutide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements doses of IDegLira will be titrated individually twice per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose >130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IDegLira could be titrated to 50 dose steps (50 U insulin degludec plus 1.8 mg liraglutide).
Study NCT04196231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IGlarLixi
Description: IGlarLixi will be started at 10 dose steps (10 U insulin glargine plus 5 mcg lixisenatide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements, doses of IGlarLixi will be titrated individually once per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose >130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IGlarLixi could be titrated to 60 dose steps (60 U insulin degludec plus 20 mcg lixisenatide).
Study NCT04196231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin/Canaglifozin
Description: Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose >130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to canaglifozin, according to the current clinical practice and the drugs' data sheet. Canagliflozin will be started at 100 mg daily per oral administration, and augmented to 300 mg/per day if required (HbA1c >7.5 after 12 weeks).
Study NCT04196231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin/Dapaglifozin
Description: Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose >130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to dapaglifozin, according to the current clinical practice and the drugs' data sheet. Dapagliflozin will be started at 10 mg daily per oral administration
Study NCT04196231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin/Empaglifozin
Description: Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose >130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to empaglifozin, according to the current clinical practice and the drugs' data sheet. Empagliflozin will be started at 10 mg daily per oral administration, and augmented to 25 mg/per day if required (HbA1c >7.5 after 12 weeks).
Study NCT04196231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal Bolus
Description: Patients in this arm will continue the basal insulin (glargine, degludec or glargine-300) used before the randomization. The insulin titration will be guided by the medical staff, according to the following algorithm: adding 2 units of basal insulin for prebreakfast plasma glucose >130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units of basal insulin for prebreakfast plasma glucose \< 80 mg/dL. The short acting insulin analogue (lispro, aspart or glulisine) will be started at the dosage of 4 units before meals (3 times per day) and will be titrated twice a week until achieving pre-prandial glucose values ranging from 80-130 mg/dL.
Study NCT02039687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA 290
Description: A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
Study NCT02039687 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation buffer
Study NCT03405324 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: a single session of tDCS over the primary motor cortex with constant current of 2mA intensity will be applied for 20 minutes with a 5-second ramp phase at the beginning.
Study NCT03405324 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham tDCS
Study NCT03698851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guidor® and Guidor easy-graft® CRYSTAL
Description: A compound of biphasic calcium phosphate, 60 % hydroxyapatite and 40 % beta-tricalcium phosphate. The beta-tricalcium phosphate component completely resorbs via physiological dissolution in 5-15 months, while the interconnected hydroxyapatite remains embedded in the implantation site and forms an integrated long term osteoconductive scaffold with new bone.
Study NCT03698851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guidor® and Guidor easy-graft® CLASSIC
Description: Phase-pure beta-tricalcium phosphate that offers complete resorption via physiological dissolution in 5-15 months. This material has been used in oral surgery for more than 25 years and there are extensive research available on it.
Study NCT04453189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Participant will receive famotidine in fasted condition on Day 1 in assigned treatment sequence.
Study NCT05782660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash Benefit
Description: Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021.
Study NCT05782660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Cash Benefit
Description: No monthly cash benefit.
Study NCT01795950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Description: intravenous administration of a single dose of PLX-PAD cells
Study NCT03112473 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task-orientated training
Description: Task-Oriented Training (TOT) is a goal-directed exercise therapy, which help the people derive optimal control strategies for solving specific motor problems in real environment. In this study, TOT included stretching exercises, mobilizing exercise, strengthening exercises, seated reaching tasks, dexterity training and bimanual practice.
Study NCT03112473 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Task-orientated training
Description: Task-Oriented Training (TOT) is a goal-directed exercise therapy, which help the people derive optimal control strategies for solving specific motor problems in real environment. In this study, TOT included stretching exercises, mobilizing exercise, strengthening exercises, seated reaching tasks, dexterity training and bimanual practice.
Study NCT03112473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: The stimulator was 120z Dual-Channel TENS Unit (ITO PHYSITHERAPY\&REHABILITION CO., LTD, Tokyo, Japan). The parameter (100 Hz, 0.2 ms square pulses, intensity barely below the motor threshold) of TENS followed our previous study
Study NCT03112473 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: The stimulator was 120z Dual-Channel TENS Unit (ITO PHYSITHERAPY\&REHABILITION CO., LTD, Tokyo, Japan). The parameter (100 Hz, 0.2 ms square pulses, intensity barely below the motor threshold) of TENS followed our previous study
Study NCT03112473 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham electrical nerve stimulation
Description: A identical-looking TENS devices that electrical circuit has been disconnected.
Study NCT03863548 — intervention group
Intervention type: OTHER
Intervention: complication
Description: collection of post-operative bleeding complications
Study NCT00763841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Stimulation will be given daily at a particular site for three days a week
Study NCT00763841 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Study NCT03516461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Fecal microbiota transplantation for patients via nasointestinal tube or gastroscopy or colonic TET tube
Study NCT03222128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR
Description: Implantation of the SAPIEN 3
Study NCT00174369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Description: 15 mg BID
Study NCT03034824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP+940±15 nm diode laser
Description: In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the 940±15 nm diode laser.
Study NCT03034824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP+Er,Cr:YSGG laser
Description: In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the Er,Cr:YSGG laser.
Study NCT03034824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)-Control
Description: Only Non-surgical periodontal treatment
Study NCT04629287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPCXM18
Description: KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route
Study NCT03105024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (e.g., description of details regarding the virtual reality environment)
Study NCT00456235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophénolate Mofétil
Study NCT04629287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KPCXM18
Description: KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route
Study NCT04629287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo,blind,freeze-dried powder,ascending doses，Intravenous route
Study NCT04629287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo,blind,freeze-dried powder,ascending doses，Intravenous route
Study NCT00193921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: IV, 25mg/m2, days 1, 8, 22
Study NCT00193921 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High dose Radiotherapy
Description: External beam radiation, 40 Gy/20#/5 per week
Study NCT00193921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 200mg (flat dose) IV days 1, 8, 15
Study NCT00193921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20mg/m2, IV, weekly
Study NCT00456235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophénolate Mofétil
Study NCT00456235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporine A
Study NCT00193921 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Radiotherapy
Description: External beam radiation, 30 Gy/15#/5 per week
Study NCT03559647 — intervention group
Intervention type: DRUG
Intervention: Atezolizumab
Description: Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).
Study NCT02450162 — intervention group
Intervention type: PROCEDURE
Intervention: lateral rectus recession (bilateral)
Description: Two types of recession (conventional or hang-back method) are typical surgeries for correcting intermittent exotropia. It depends on surgeon's decision at the time of surgery.
Study NCT00456235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporine A
Study NCT00456235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT02504567 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Laser ablation
Description: Pulmonary vein isolation using the laser ablation catheter
Study NCT02504567 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RF ablation
Description: Pulmonary vein isolation using the RF ablation catheter
Study NCT00733044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized Care
Description: The intervention consists of the integration of integral tinnitus management provided by a specialized tinnitus centre in the health care system. The tinnitus centre offers care following a stepped-care approach with two levels. The first level of intervention consists of audiological diagnostics and intervention, a tinnitus educational group session and a individual consult with a clinical psychologist. For patients with mild complaints this basic intervention is expected to suffice. For patients with moderate to severe complaints a second level of intervention exists. This level of intervention consists of combinations of the following therapies: Cognitive Behavioural Therapy (CBT), Attention Diversion (AD), exposure techniques, and Relaxation Therapy (RT).
Study NCT00733044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care consists of a standardized version of treatment that is currently applied in peripheral audiological centres throughout the Netherlands. A telephone survey was conducted amongst all audiological centres (n=28) in the Netherlands. The results of this survey determined the content of the usual care treatment protocol in the current study. The treatment consists of audiological diagnostics and intervention and, if necessary, one or more consults with a social worker with a maximum of ten one hour sessions.
Study NCT04193475 — intervention group
Intervention type: OTHER
Intervention: Analysis
Description: No intervention planned. Novel analysis of echocardiographic data.
Study NCT01269697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrof Total
Description: 2 capsules 2 times per day during 6 month
Study NCT01269697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nutrof total
Description: 2 capsules 2 times per day during 6 month